Beta Nerve Growth Factor (Beta NGF or NGF) – Drugs in Development, 2021

Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 11 molecules. The latest report Beta Nerve Growth Factor – Drugs in Development, 2021, outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Beta Nerve Growth Factor (Beta NGF or NGF) – Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI. The molecules developed by companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3, 1, 4 and 1 respectively.

Report covers products from therapy areas Central Nervous System, Cardiovascular, Ophthalmology, Dermatology, Hematological Disorders and Immunology which include indications Pain, Osteoarthritis Pain, Cancer Pain, Amyotrophic Lateral Sclerosis, Cardiac Arrest, Diabetic Neuropathic Pain, Glaucoma, Keratitis, Low Back Pain, Lung Transplant Rejection, Myocardial Infarction, Optic Nerve Injury, Parkinson's Disease, Peripheral Nerve Injury, Post-Operative Pain, Pressure Ulcers, Retinitis Pigmentosa (Retinitis), Sicca Syndrome (Sjogren) and Sickle Cell Disease.

Furthermore, this report also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)

– The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects

– The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AstraZeneca Plc

Dartbio Pharmaceuticals Co Ltd

Fujimoto Pharmaceutical Corp

MimeTech Srl

Pfizer Inc

Regeneron Pharmaceuticals Inc

Serometrix LLC

Staidson BioPharma Inc

Zhuhai Trinomab Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Beta Nerve Growth Factor (Beta NGF or NGF) - Overview

Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Dartbio Pharmaceuticals Co Ltd

Fujimoto Pharmaceutical Corp

MimeTech Srl

Pfizer Inc

Regeneron Pharmaceuticals Inc

Serometrix LLC

Staidson BioPharma Inc

Zhuhai Trinomab Biotechnology Co Ltd

Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles

DS-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fasinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-7352 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Nerve Growth Factor for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate NGF Beta for Optic Nerve Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NGF for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tanezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udonitrectag - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products

Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products

Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones

Featured News & Press Releases

Mar 25, 2021: Joint FDA advisory committee votes on application for tanezumab for the treatment of osteoarthritis pain

Jan 01, 2021: Congratulations to DartsBio Pharmaceutical for analgesic DS002 injection approved for clinical trial by NMPA

Jun 19, 2020: New therapy reduces chronic low back pain in large international study

Jun 19, 2020: New therapy reduces chronic low back pain in large international study

Mar 02, 2020: U.S. FDA accepts regulatory submission for Tanezumab, a potential first-in-class treatment for patients with chronic pain due to moderate-to-severe osteoarthritis

Jul 10, 2019: Drug shows benefit for osteoarthritis patients

Apr 23, 2019: Pfizer and Lilly report mixed results from trial of tanezumab

Feb 20, 2019: Pfizer-Lilly’s tanezumab reduces chronic low back pain in trial

Jan 29, 2019: Pfizer and Lilly announce top-line results from second phase 3 study of Tanezumab in osteoarthritis pain

Dec 05, 2018: Recordati receives orphan drug designation for its investigational treatment for neurotrophic keratitis

Oct 24, 2018: Pfizer and Eli Lilly report positive Phase III tanezumab trial results

Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints

Jul 20, 2018: Pfizer and Eli Lilly report positive results from Phase III tanezumab

Aug 17, 2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis

Jun 13, 2017: Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by AstraZeneca Plc, 2021

Pipeline by Dartbio Pharmaceuticals Co Ltd, 2021

Pipeline by Fujimoto Pharmaceutical Corp, 2021

Pipeline by MimeTech Srl, 2021

Pipeline by Pfizer Inc, 2021

Pipeline by Regeneron Pharmaceuticals Inc, 2021

Pipeline by Serometrix LLC, 2021

Pipeline by Staidson BioPharma Inc, 2021

Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports